RACE ONCOLOGY LTD

14.0%

$1.39

Market Cap $240.6M

Healthcare Biotechnology

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a... Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.More

Corporate Spotlight

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
View the full Corporate Spotlight

RAC Accelerates Game-Changing Cancer Drug

Latest Threads

Tag

Subject

RAC

Ann: Appendix 4E & Annual Report

03/09/25

5.7K

03/09/25

Last post DrSanchez

5.7K

RAC Biotech

RAC - Charts & Price Action

445 446 447

03/09/25

26K

10M

03/09/25

Last post FreeBobby2002

26K

10M

RAC

RAC media coverage

45 46 47

03/09/25

2.8K

1.0M

03/09/25

Last post ma420

2.8K

1.0M

RAC

Ann: First Hong Kong Site Activated for RC220 Trial

03/09/25

7.3K

03/09/25

Last post Hunterr

7.3K

RAC

Ann: Application for quotation of securities - RAC

02/09/25

2.4K

02/09/25

Last post depps89

2.4K

RAC

General Comments / Chat

234 235 236

02/09/25

14K

5.3M

02/09/25

Last post Boffin99

14K

5.3M

RAC

Ann: First Patient Safely Combine Dosed in Phase 1 RC220 Trial

3 4 5

02/09/25

269

80K

02/09/25

Last post johndprent

269

80K

RAC

Ann: Race Oncology Upcoming 2025 Investor Events

2 3

01/09/25

175

43K

01/09/25

Last post Hunterr

175

43K

RAC

Ann: Termination of City of Hope Global IP License

2 3

31/08/25

176

62K

31/08/25

Last post arsenal1954

176

62K

RAC

Industry news

52 53 54

31/08/25

3.2K

1.1M

31/08/25

Last post couldwellb

3.2K

1.1M

RAC

Ann: Quarterly Activity Report and Appendix 4C

28/08/25

112

34K

28/08/25

Last post asx11

112

34K

RAC

Ann: Appendix 4G

26/08/25

363

26/08/25

Last post

ASX News

363

RAC

Ann: Corporate Governance Statement

26/08/25

292

26/08/25

Last post

ASX News

292

RAC

Cardioprotection thread

19 20 21

23/08/25

1.2K

422K

23/08/25

Last post Boffin99

1.2K

422K

RAC

Ann: RC220 Human Ethics Approvals Received in Hong Kong

23/08/25

13K

23/08/25

Last post Rossi70

13K

RAC

megan baldwin

23/08/25

11K

23/08/25

Last post dalts66

11K

See All Discussions

Corporate Spotlight

ABOUT US

Timeline

Application for quotation of securities - RAC
02 Sep 13:55	Share

First Hong Kong Site Activated for RC220 Trial
02 Sep 09:21	Share

Appendix 4G
26 Aug 16:48	Share

Corporate Governance Statement
26 Aug 16:47	Share

Appendix 4E & Annual Report
26 Aug 16:45	Share

Phase 2 Bisantrene AML Trial Results Published
04 Aug 13:57	Share

Notification regarding unquoted securities - RAC
24 Jul 16:34	Share

June 2025 Quarterly Activity Report and Appendix 4C
23 Jul 08:28	Share

Race Oncology Upcoming 2025 Investor Events
15 Jul 13:29	Share

RC220 Human Ethics Approvals Received in Hong Kong
10 Jul 09:07	Share

Application for quotation of securities - RAC
26 Jun 13:49	Share

Application for quotation of securities - RAC
19 Jun 14:35	Share

First Patient Safely Combine Dosed in Phase 1 RC220 Trial
19 Jun 08:56	Share

Termination of City of Hope Global IP License
17 Jun 08:57	Share

Application for quotation of securities - RAC
06 Jun 11:54	Share

Notification of cessation of securities - RAC
03 Jun 10:27	Share

Race Gold Coast Brisbane Investor Events
02 Jun 12:14	Share

Application for quotation of securities - RAC
29 May 16:11	Share

Application for quotation of securities - RAC
22 May 11:14	Share

Application for quotation of securities - RAC
07 May 11:09	Share

Notification of cessation of securities - RAC
06 May 15:51	Share

Race Announces Key Senior Clinical Team Appointments
05 May 08:57	Share

First Patient Dosed Safely in RC220 Phase 1 Trial
01 May 08:57	Share

March 2025 Quarterly Activity Report and Appendix 4C
23 Apr 08:41	Share

Enrolment Opened at Second Site for RC220 Phase 1 Trial
22 Apr 08:56	Share

RC220 Phase 1 Trial Opens for Patient Enrolment
03 Apr 08:57	Share

Ethics approval for RC220 Trial at Gosford Wyong Hospitals
31 Mar 17:41	Share

Race Initiates First AU Site for Phase 1 Solid Tumour Trial
27 Mar 15:53	Share

Race Investor Presentation
17 Mar 16:53	Share

Race Online Investor Briefing Invitation
14 Mar 11:08	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.39		Change 0.170(14.0%)		Mkt cap ! $240.6M

Open	High	Low	Value	Volume
$1.23	$1.39	$1.23	$594.5K	453.5K

Buyers (Bids)

No.	Vol.	Price($)
1	2097	$1.39

Sellers (Offers)

Price($)	Vol.	No.
$1.39	14870	2

View Market Depth

No.	Vol.	Price($)
1	2097	1.385
1	5000	1.350
2	4606	1.330
3	22000	1.300
2	20696	1.280

Price($)	Vol.	No.
1.390	7000	1
1.395	716	1
1.410	2127	1
1.440	706	1
1.480	263	1

Last trade - 16.10pm 03/09/2025 (20 minute delay)


Last $1.38		Change 0.170 ( 12.1 %)
Open	High	Low	Volume
$1.24	$1.38	$1.24	37348
Last updated 15.55pm 03/09/2025 ?

RAC (ASX) Chart

RACE ONCOLOGY LTD

Corporate Spotlight

Latest Threads

Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion?

Corporate Spotlight

Timeline

Featured News

Latest Videos

Race Oncology accelerates gamechanging cancer drug

02 Jul 2025 09:48 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

14 May 2024 09:56 (AEST)

Race Oncology (ASX:RAC) strikes contracts to start observational breast cancer trial

13 Mar 2023 15:00 (AEDT)

Latest Articles

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News